Liver fibrogenesis: A new role for the renin-angiotensin system

Antioxidants and Redox Signaling

Volumn 7, Issue 9-10, 2005, Pages 1346-1355

  Bataller, Ramón ^a,c   Sancho Bru, Pau ^a   Ginès, Pere ^a   Brenner, David A ^b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANTIFIBROTIC AGENT; CANDESARTAN; CAPTOPRIL; CELL NUCLEUS RECEPTOR; CYTOCHROME P450 2E1; EPIDERMAL GROWTH FACTOR; IRBESARTAN; LISINOPRIL; LOSARTAN; OLMESARTAN; PERINDOPRIL; PLATELET DERIVED GROWTH FACTOR; RAS PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SMAD PROTEIN; THROMBOCYTE ACTIVATING FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE;

CELL INFILTRATION; CELL PROLIFERATION; CHRONIC LIVER DISEASE; COLLAGEN SYNTHESIS; FIBROGENESIS; HUMAN; INFLAMMATORY CELL; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER FIBROSIS; MYOFIBROBLAST; OXIDATION REDUCTION REACTION; PATHOGENESIS; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; STELLATE CELL; TISSUE REPAIR;

ANGIOTENSIN II; ANIMALS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS; CYTOKINES; FIBROSIS; HEPATOCYTES; HUMANS; INFLAMMATION; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; NADPH OXIDASE; RATS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 24144432258     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2005.7.1346     Document Type: Review

References (85)

1. Arroyo V, Bosch J, Mauri M, Viver J, Mas A, Rivera F, and Rodes J. Renin, aldosterone and renal haemodynamics in cirrhosis with ascites. Eur J Clin Invest 9: 69-73, 1979.
2. Arthur MJ. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 122: 1525-1528, 2002.
3. Bataller R and Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis 21: 437-451, 2001.
4. Bataller R, Gines P, Nicolas JM, Gorbig MN, Garcia-Ramallo E, Gasull X, Bosch J, Arroyo V, and Rodes J. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 118: 1149-1156, 2000.
5. Bataller R, Gines P, Sancho-Bru P, Lora J, Sole M, Nicolas J, Jimenez W, Arroyo V, and Rodes J. Human activated hepatic stellate cells express the renin-angiotensin system and secrete angiotensin II. Gastroenterology 125: 117-125, 2003.
6. Bataller R, North KE, and Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 37: 493-503, 2003.
7. Bataller R, Gabele E, Schoonhoven R, Morris T, Lehnert M, Yang L, Brenner DA, and Rippe RA. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am J Physiol Gastrointest Liver Physiol 285: G642-651, 2003.
8. Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J, Qian T, Schoonhoven R, Hagedorn CH, Lemasters JJ, and Brenner DA. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 112: 1383-1394, 2003.
9. Bataller R and Brenner DA. Liver fibrosis. J Clin Invest 115: 209-218, 2005.
10. Bataller R, Gabele E, Parsons CJ, Morris T, Yang L, Schoonhoven R, Brenner DA, and Rippe RA. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology 41: 1046-1055, 2005.
11. Benyon RC and Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 21: 373-384, 2001.
12. Berenguer M, Crippin J, Gish R, Bass N, Bostrom A, Netto G, Alonzo J, Garcia-Kennedy R, Rayon JM, and Wright TL. A model to predict severe HCV-related disease following liver transplantation. Hepatology 38: 34-41, 2003.
13. Berk BC. Redox signals that regulate the vascular response to injury. Thromb Haemost 82: 810-817, 1999.
14. Bissell DM. Chronic liver injury, TGF-beta, and cancer. Exp Mol Med 33: 179-190, 2001.
15. Caligiuri A, De Franco RM, Romanelli RG, Gentilini A, Meucci M, Failli P, Mazzetti L, Rombouts K, Geerts A, Vanasia M, Gentilini P, Marra F, and Pinzani M. Antifibrogenic effects of canrenone, an antialdosteronic drug, on human hepatic stellate cells. Gastroenterology 124: 504-520, 2003.
16. Canbay A, Friedman S, and Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 39: 273-278, 2004.
17. Cardenas A, Bataller R, and Arroyo V. Mechanisms of ascites formation. Clin Liver Dis 4: 447-465, 2000.
18. Casini A, Ceni E, Salzano R, Biondi P, Parola M, Galli A, Foschi M, Caligiuri A, Pinzani M, and Surrenti C. Neutrophil-derived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells: role of nitric oxide. Hepatology 25: 361-367, 1997.
19. Crabb DW. Pathogenesis of alcoholic liver disease: newer mechanisms of injury. Keio J Med 48: 184-188, 1999.
20. Croquet V, Moal F, Veal N, Wang J, Oberti F, Roux J, Vuillemin E, et al. Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. J Hepatol 37: 773-780, 2002.
21. Czaja AJ and Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 40: 646-652, 2004.
22. Delcayre C and Swynghedauw B. Molecular mechanisms of myocardial remodeling. The role of aldosterone. J Mol Cell Cardiol 34: 1577-1584, 2002.
23. Dixon JB, Bhathal PS, Jonsson JR, Dixon AF, Powell EE, and O'Brien PE. Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. J Hepatol 39: 967-971, 2003.
24. Dufour JF, DeLellis R, and Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 127: 981-985, 1997.
25. Forbes SJ, Russo FP, Rey V, Burra P, Rugge M, Wright NA, and Alison MR. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 126: 955-963, 2004.
26. Friedman SL. Liver fibrosis-from bench to bedside. J Hepatol 38 Suppl 1: S38-S53, 2003.
27. Harrison SA, Torgerson S, Hayashi P, Ward J, and Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 98: 2485-2490, 2003.
28. Huang YT, Hsu YC, Chen CJ, Liu CT, and Wei YH. Oxidative-stress-related changes in the livers of bile-duct-ligated rats. J Biomed Sci 10: 170-178, 2003.
29. Ikejima K, Lang T, Zhang YJ, Yamashina S, Honda H, Yoshikawa M, Hirose M, Enomoto N, Kitamura T, Takei Y, and Sato N. Expression of leptin receptors in hepatic sinusoidal cells. Comp Hepatol 3 Suppl 1: S12, 2004.
30. Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson MD, Purdie DM, and Powell EE. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 121: 148-155, 2001.
31. Kamada Y, Tamura S, Kiso S, Fukui K, Doi Y, Ito N, Terui Y, Saito T, Watanabe H, Togashi H, Kawata S, and Matsuzawa Y. Angiotensin II stimulates the nuclear translocation of Smad2 and induces PAI-1 mRNA in rat hepatic stellate cells. Hepatol Res 25: 296-305, 2003.
32. Kinnman N and Housset C. Peribiliary myofibroblasts in biliary type liver fibrosis. Front Biosci 7: d496-d503, 2002.
33. Kmiec Z. Cooperation of liver cells in health and disease. Adv Anat Embryol Cell Biol 161: III-XIII, 1-151, 2001.
34. Knolle PA, Uhrig A, Hegenbarth S, Loser E, Schmitt E, Gerken G, and Lohse AW. IL-10 down-regulates T cell activation by antigen-presenting liver sinusoidal endothelial cells through decreased antigen uptake via the mannose receptor and lowered surface expression of accessory molecules. Clin Exp Immunol 114: 427-433, 1998.
35. Kurikawa N, Suga M, Kuroda S, Yamada K, and Ishikawa H. An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. Br J Pharmacol 139: 1085-1094, 2003.
36. 4-inducing rat hepatic fibrosis. Zhonghua Can Zang Bing Za Zhi 12: 32-34, 2004.
37. 4-inducing rat hepatic fibrogenesis, Zhonghua Yi Xue Za Zhi 83: 1241-1245, 2003.
38. 4. Chin Med J (Engl) 114: 64-68, 2001.
39. Lieber CS. Hepatic and metabolic effects of alcohol (1966 to 1973). Gastroenterology 65: 821-846, 1973.
40. Lieber CS. New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments. Curr Gastroenterol Rep 6: 60-65, 2004.
41. Liu TZ, Lee O, Chern CL, Cheng JT, Stern A, and Tsai LY. Free radical-triggered hepatic injury of experimental obstructive jaundice of rats involves overproduction of proinflammatory cytokines and enhanced activation of nuclear factor kappaB. Ann Clin Lab Sci 31: 383-390, 2001.
42. Marra F. Chemokines in liver inflammation and fibrosis. Front Biosci 7: d1899-d1914, 2002.
43. Medina J, Arroyo AG, Sanchez-Madrid F, and Moreno-Otero R. Angiogenesis in chronic inflammatory liver disease. Hepatology 39: 1185-1195, 2004.
44. Miyahara T, Schrum L, Rippe R, Xiong S, Yee HF Jr, Motomura K, Anania FA, Willson TM, and Tsukamoto H. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 275: 35715-35722, 2000.
45. Moller S, Bendtsen F, and Henriksen JH. Vasoactive substances in the circulatory dysfunction of cirrhosis. Scand J Clin Lab Invest 61: 421-429, 2001.
46. Naito M, Hasegawa G, Ebe Y, and Yamamoto T. Differentiation and function of Kupffer cells. Med Electron Microsc 37: 16-28, 2004.
47. Nieto N, Friedman SL, and Cederbaum AI. Cytochrome P450 2E1-derived reactive oxygen species mediate paracrine stimulation of collagen I protein synthesis by hepatic stellate cells. J Biol Chem 277: 9853-9864, 2002.
48. Ohhira M, Ohtake T, Matsumoto A, Saito H, Ikuta K, Fujimoto Y, Ono M, Toyokuni S, and Kohgo Y. Immunohistochemical detection of 4-hydroxy-2-nonenal- modified-protein adducts in human alcoholic liver diseases. Alcohol Clin Exp Res 22: 145S-149S, 1998.
49. Ohishi T, Saito H, Tsusaka K, Toda K, Inagaki H, Hamada Y, Kumagai N, Atsukawa K, and Ishii H. Anti-fibrogenic effect of an angiotensin converting enzyme inhibitor on chronic carbon tetrachloride-induced hepatic fibrosis in rats. Hepatol Res 21: 147-158, 2001.
50. Paizis G, Cooper ME, Schembri JM, Tikellis C, Burrell LM, and Angus PW. Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology 123: 1667-1676, 2002.
51. Paizis G, Gilbert RE, Cooper ME, Murthi P, Schembri JM, Wu LL, Rumble JR, Kelly DJ, Tikellis C, Cox A, Smallwood RA, and Angus PW. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol 35: 376-385, 2001.
52. Parola M and Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol 35: 297-306, 2001.
53. Parola M, Robino G, Marra F, Pinzani M, Bellomo G, Leonarduzzi G, Chiarugi P, Camandola S, Poli G, Waeg G, Gentilini P, and Dianzani MU. HNE interacts directly with JNK isoforms in human hepatic stellate cells. J Clin Invest 102: 1942-1950, 1998.
54. Pinzani M, Marra F, and Carloni V. Signal transduction in hepatic stellate cells. Liver 18: 2-13, 1998.
55. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, Purdie DM, and Jonsson JR. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 31: 828-833, 2000.
56. Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, Myers RP, Muntenau M, Ratziu V, Manns M, Vogel A, Capron F, Chedid A, and Bedossa P. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 38: 257-265, 2003.
57. Ramalho LN, Ramalho FS, Zucoloto S, Castro-e-Silva OJ, Correa FM, Elias JJ, and Magalhaes JF. Effect of losartan, an angiotensin II antagonist, on secondary biliary cirrhosis. Hepatogastroenterology 49: 1499-1502, 2002.
58. Ramos SG, Montenegro AP, Goissis G, and Rossi MA. Captopril reduces collagen and mast cell and eosinophil accumulation in pig serum-induced rat liver fibrosis. Pathol Int 44: 655-661, 1994.
59. Reeves HL and Friedman SL. Activation of hepatic stellate cells-a key issue in liver fibrosis. Front Biosci 7: d808-d826, 2002.
60. Reif S, Lang A, Lindquist JN, Yata Y, Gabele E, Scanga A, Brenner DA, and Rippe RA. The role of focal adhesion kinase-phosphatidylinositol 3-kinase-Akt signaling in hepatic stellate cell proliferation and type I collagen expression. J Biol Chem 278: 8083-8090, 2003.
61. Rimola A, Londono MC, Guevara G, Bruguera M, Navasa M, Forms X, Garcia-Retortillo M, Garcia-Valdecasas JC, and Rodes J. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplanation. Transplantation 78: 686-691, 2004.
62. Rombouts K, Niki T, Wielant A, Hellemans K, Schuppan D, Kormoss N, and Geerts A. Effect of aldosterone on collagen steady state levels in primary and subcultured rat hepatic stellate cells. J Hepatol 34: 230-238, 2001.
63. Schuppan D, Krebs A, Bauer M, and Hahn EG. Hepatitis C and liver fibrosis. Cell Death Differ 10 Suppl 1: S59-S67, 2003.
64. Skrtic S, Wallenius K, Gressner AM, and Jansson JO. Characterization of hepatocyte-derived mitogenic activity on hepatic stellate cells. Liver 20: 157-164, 2000.
65. Sokol RJ, Devereaux MW, and Khandwala R. Effect of oxypurinol, a xanthine oxidase inhibitor, on hepatic injury in the bile duct-ligated rat. Pediatr Res 44: 397-401, 1998.
66. Sonkodi S and Mogyorosi A. Treatment of diabetic nephropathy with angiotensin II blockers. Nephrol Dial Transplant 18 Suppl 5: v21-v23, 2003.
67. Sun Y and Weber KT. Cardiac remodelling by fibrous tissue: role of local factors and circulating hormones. Ann Med 30 Suppl 1:3-8, 1998.
68. Svegliati Baroni G, D'Ambrosio L, Ferretti G, Casini A, Di Sario A, Salzano R, Ridolfi F, Saccomanno S, Jezequel AM, and Benedetti A. Fibrogenic effect of oxidative stress on rat hepatic stellate cells. Hepatology 27: 720-726, 1998.
69. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 79: 215-262, 1999.
70. Terui Y, Saito T, Watanabe H, Togashi H, Kawata S, Kamada Y, and Sakuta S. Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology 36: 1022, 2002.
71. Tuncer I, Ozbek H, Ugras S, and Bayram I. Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat. The effect of AT1-R blocker on the hepatic fibrosis. Exp Toxicol Pathol 55: 159-166, 2003.
72. Viedt C, Soto U, Krieger-Brauer HI, Fei J, Elsing C, Kubler W, and Kreuzer J. Differential activation of mitogen-activated protein kinases in smooth muscle cells by angiotensin II: involvement of p22phox and reactive oxygen species. Arterioscler Thromb Vasc Biol 20: 940-948, 2000.
73. Vrba J and Modriansky M. Oxidative burst of Kupffer cells: target for liver injury treatment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 146: 15-20, 2002.
74. Wei H, Li D, Lu H, Zhan Y, Wang Z, Huang X, Pan Q, and Xu Q. Effects of angiotensin II receptor blockade on hepatic fibrosis in rats. Zhonghua Gan Zang Bing Za Zhi 8: 302-304, 2000.
75. 4. World J Gastroenterol 6: 504-545, 2000.
76. 4. World J Gastroenterol 6: 824-828, 2000.
77. Weintraub NL. Nox response to injury. Arterioscler Thromb Vasc Biol 22: 4-5, 2002.
78. Wheeler MD, Kono H, Yin M, Nakagami M, Uesugi T, Arteel GE, Gabele E, Rusyn I, Yamashina S, Froh M, Adachi Y, Iimuro Y, Bradford BU, Smutney OM, Connor HD, Mason RP, Goyert SM, Peters JM, Gonzalez FJ, Samulski RJ, and Thurman RG. The role of Kupffer cell oxidant production in early ethanol-induced liver disease. Free Radic Biol Med 31: 1544-1549, 2001.
79. Yang L, Bataller R, Dulyx J, Coffman TM, Gines P, Rippe RA, and Brenner DA. Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. J Hepatol 43: 317-323, 2005.
80. Yoshiji H, Kuriyama S, and Fukui H. Angiotensin-I-converting enzyme inhibitors may be an alternative antiangiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol 23: 348-356, 2002.
81. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, and Fukui H. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 34: 745-750, 2001.
82. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Yanase K, Namisaki T, Yamazaki M, Tsujinoue H, Imazu H, and Fukui H. Angiotensin-II induces the tissue inhibitor of metalloproteinases-1 through the protein kinase-C signaling pathway in rat liver fibrosis development. Hepatol Res 27: 51-56, 2003.
83. Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T, Imazu H, Yanase K, Kuriyama S, and Fukui H. Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J Hepatol 37: 22-30, 2002.
84. Zhang YJ, Yang XS, Wu PS, Liao GQ, Yang GP, Zhang XF, and Chen XQ. Expression of AT(1a)mRNA in rat hepatic stellate cells and its effects on cell growth collagen production. Chin Med J (Engl) 117: 772-774, 2004.
85. Zhong Z, Froh M, Wheeler MD, Smutney O, Lehmann TG, and Thurman RG. Viral gene delivery of superoxide dismutase attenuates experimental cholestasis-induced liver fibrosis in the rat. Gene Ther 9: 183-191, 2002.